CORRIGENDUM: New Insights for Low Dosing With the New P2Y₁₂ Inhibitors

– Lesson From the East –

The authors apologize for the incorrections in the lines 24 to 29, page 2841. The correct spelling is given below.

Incorrect:

In the secondary prevention PEGASUS trial (NCT01225562) trial, a low-dosing strategy is also tested with ticagrelor (60 mg twice daily) in comparison with clopidogrel, both in association with aspirin, while the standard dose of ticagrelor (90 mg twice a day) is also tested in a third arm with aspirin alone.

Correct:

In the secondary prevention PEGASUS trial (NCT01225562) trial, a low-dosing strategy is also tested with ticagrelor (60 mg twice daily) in comparison with matching placebo, both in association with aspirin, while the standard dose of ticagrelor (90 mg twice a day) is also tested in a third arm with aspirin.